Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patent cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers
Subscribe to our email newsletter
Oncolytics Biotech (Oncolytics) has reported that it has been granted its 32nd US Patent no 7582289, entitled ‘Viruses for the Treatment of Cellular Proliferative Disorders.’ The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.
Mary Ann Dillahunty, vice president of intellectual property for Oncolytics, said: This US patent expands our intellectual property portfolio regarding oncolytic viruses, in addition to reovirus, that can be modified to grow selectively in Ras-mediated cancers.
Including the patent issued today, Oncolytics has now secured five US patents covering the use of other oncolytic viruses to treat Ras-mediated cancers. Patents covering similar subject matter have been granted in other jurisdictions as well.